Delta-Fly Pharma Updates on DFP-10917 Clinical Trials

MT Newswires Live

2025/11/06

Delta-Fly Pharma (TYO:4598) said data cleaning for the interim analysis of its Phase 3 U.S. trial of DFP-10917 monotherapy for end-stage acute myeloid leukemia is taking longer than planned, according to a Thursday filing on the Tokyo Stock Exchange.

Efficacy data from trial sites and bone marrow analysis at the MD Anderson Cancer Center are now available, and the company plans to submit results to the Data Safety Management Board once analysis is complete.

A Phase 1/2 study of DFP-10917 combined with venetoclax is progressing and expected to complete patient enrollment soon, with efficacy and safety evaluations by a monitoring committee to follow. Delta-Fly said it may collaborate with a global pharmaceutical partner for Phase 3 studies.

In the U.S., an expanded Phase 1 trial of DFP-14927, a drug delivery system for DFP-10917, showed improved disease control but no tumor shrinkage in colorectal cancer patients. The company will continue testing in pancreatic cancer.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581057432"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581057432\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581057432?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 17:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581057432","market":"us","top_or_hot":-1,"title":"Delta-Fly Pharma Updates on DFP-10917 Clinical Trials","media":"MT Newswires Live","content":"<html><body><p> Delta-Fly Pharma (TYO:4598) said data cleaning for the interim analysis of its Phase 3 U.S. trial of DFP-10917 monotherapy for end-stage acute myeloid leukemia is taking longer than planned, according to a Thursday filing on the Tokyo Stock Exchange.</p><p>Efficacy data from trial sites and bone marrow analysis at the MD Anderson Cancer Center are now available, and the company plans to submit results to the Data Safety Management Board once analysis is complete.</p><p>A Phase 1/2 study of DFP-10917 combined with venetoclax is progressing and expected to complete patient enrollment soon, with efficacy and safety evaluations by a monitoring committee to follow. Delta-Fly said it may collaborate with a global pharmaceutical partner for Phase 3 studies.</p><p>In the U.S., an expanded Phase 1 trial of DFP-14927, a drug delivery system for DFP-10917, showed improved disease control but no tumor shrinkage in colorectal cancer patients. The company will continue testing in pancreatic cancer.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Delta-Fly Pharma Updates on DFP-10917 Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDelta-Fly Pharma Updates on DFP-10917 Clinical Trials\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-11-06 17:26</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Delta-Fly Pharma (TYO:4598) said data cleaning for the interim analysis of its Phase 3 U.S. trial of DFP-10917 monotherapy for end-stage acute myeloid leukemia is taking longer than planned, according to a Thursday filing on the Tokyo Stock Exchange.</p><p>Efficacy data from trial sites and bone marrow analysis at the MD Anderson Cancer Center are now available, and the company plans to submit results to the Data Safety Management Board once analysis is complete.</p><p>A Phase 1/2 study of DFP-10917 combined with venetoclax is progressing and expected to complete patient enrollment soon, with efficacy and safety evaluations by a monitoring committee to follow. Delta-Fly said it may collaborate with a global pharmaceutical partner for Phase 3 studies.</p><p>In the U.S., an expanded Phase 1 trial of DFP-14927, a drug delivery system for DFP-10917, showed improved disease control but no tumor shrinkage in colorectal cancer patients. The company will continue testing in pancreatic cancer.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DFP","symbol_name":"Flaherty & Crumrine Dynamic","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2581057432","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581057432","pubTimestamp":1762421215,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Delta-Fly Pharma  said data cleaning for the interim analysis of its Phase 3 U.S. trial of DFP-10917 monotherapy for end-stage acute myeloid leukemia is taking longer than planned, according to a Thursday filing on the Tokyo Stock Exchange.Efficacy data from trial sites and bone marrow analysis at the MD Anderson Cancer Center are now available, and the company plans to submit results to the Data Safety Management Board once analysis is complete.A Phase 1/2 study of DFP-10917 combined with venetoclax is progressing and expected to complete patient enrollment soon, with efficacy and safety evaluations by a monitoring committee to follow. Delta-Fly said it may collaborate with a global pharmaceutical partner for Phase 3 studies.In the U.S., an expanded Phase 1 trial of DFP-14927, a drug delivery system for DFP-10917, showed improved disease control but no tumor shrinkage in colorectal cancer patients. The company will continue testing in pancreatic cancer.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DFP":"Flaherty & Crumrine Dynamic"},"translate_title":"Delta-Fly Pharma更新DFP-10917临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DFP":1.5},"content_text":"Delta-Fly Pharma (TYO:4598) said data cleaning for the interim analysis of its Phase 3 U.S. trial of DFP-10917 monotherapy for end-stage acute myeloid leukemia is taking longer than planned, according to a Thursday filing on the Tokyo Stock Exchange.Efficacy data from trial sites and bone marrow analysis at the MD Anderson Cancer Center are now available, and the company plans to submit results to the Data Safety Management Board once analysis is complete.A Phase 1/2 study of DFP-10917 combined with venetoclax is progressing and expected to complete patient enrollment soon, with efficacy and safety evaluations by a monitoring committee to follow. Delta-Fly said it may collaborate with a global pharmaceutical partner for Phase 3 studies.In the U.S., an expanded Phase 1 trial of DFP-14927, a drug delivery system for DFP-10917, showed improved disease control but no tumor shrinkage in colorectal cancer patients. The company will continue testing in pancreatic cancer.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}